Viatris Welcomes Frank D'Amelio and Michael Severino to Board
Viatris Strengthens Leadership with New Board Appointments
Viatris Inc. (NASDAQ: VTRS), a prominent global healthcare company, is making significant strides in its leadership by appointing Frank D'Amelio and Michael Severino, M.D., to its Board of Directors. This strategic move comes as part of Viatris' ongoing efforts to enhance board diversity and expertise. Current directors Rajiv Malik and Hal Korman will be retiring at the end of their terms, creating new opportunities for fresh perspectives on the Board.
Meet the New Board Members
Frank D'Amelio, a seasoned professional in the pharmaceutical industry, brings over 20 years of experience as a CFO, most notably for Pfizer. D'Amelio held various leadership roles that encompassed critical functions such as corporate finance, audit, and investor relations. His remarkable tenure included overseeing global supply operations during the challenging times of the COVID-19 pandemic.
In addition to his role at Pfizer, D'Amelio has served on the Boards of several corporations, including Humana Inc. and Hewlett Packard Enterprise Company. His academic credentials include an MBA from St. John's University and a bachelor's degree in accounting from St. Peter's University.
Michael Severino: A Leader in Drug Development
Michael Severino, M.D. is another key addition to the Viatris Board. He has an extensive background in drug development, having served as Vice Chairman and President at AbbVie Inc. Previously, he held vital positions at Amgen Inc., where he influenced global development efforts.
Dr. Severino is also a member of the Board of Directors of other innovative companies like Avantor, Inc. and Montai Therapeutics, Inc. His medical training includes an M.D. from Johns Hopkins University, alongside his residency and fellowship at Massachusetts General Hospital and Harvard Medical School.
Statements from the Board
Melina Higgins, Chair of the Board, expressed excitement about the appointments: "We are thrilled to welcome Frank and Mike to the Viatris Board. They each bring valuable experience that will benefit the Board and support our growth objectives."
Viatris' CEO, Scott A. Smith, also voiced strong support for the new board members: "Frank's financial acumen combined with Mike's expertise in drug development will be pivotal as we pursue our vision for long-term success." He further acknowledged the invaluable contributions of outgoing board members Malik and Korman.
A Legacy of Service
As outgoing directors, both Malik and Korman have left an indelible mark on the company. Malik remarked on the tremendous growth and expansion he witnessed during his tenure, emphasizing the community that has prospered through their efforts. Meanwhile, Korman reflected on his pride in being a part of the company’s evolution into a leading entity, proud to have contributed to a vision that aims to improve healthcare around the globe.
Viatris’ Commitment to Healthcare
Viatris serves a critical role in healthcare as a company that bridges generics and brand medications, striving to meet various healthcare needs worldwide. The now strengthened board will further enhance Viatris' mission to empower individuals globally, providing access to quality medicines and addressing both chronic and acute health challenges. With a robust supply chain and a promise to deliver healthcare solutions effectively, Viatris stands at the forefront of the pharmaceutical industry.
Frequently Asked Questions
Who were appointed to the Viatris Board of Directors?
Frank D'Amelio and Michael Severino, M.D., have been appointed as new members.
What are the backgrounds of the new board members?
Both have extensive experience in the pharmaceutical industry; D'Amelio is a former CFO at Pfizer and Severino has held leadership roles at AbbVie and Amgen.
Why are current directors Rajiv Malik and Hal Korman retiring?
Both are retiring at the end of their current terms, following a long and impactful service to the company.
What is Viatris' mission?
Viatris aims to empower people worldwide to live healthier lives and improve access to high-quality medicines.
What is Viatris known for in the pharmaceutical industry?
It is recognized for uniquely combining generic and brand medications to meet healthcare needs globally.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
